We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
The capital stack after Jensen
Huang's resignation was covered in the last brief. Two things are new. First, Nvidia's governance: Harvey C. Jones is the board's first-ever chair. Independent directors will keep investigating even though Huang has left, and Q3 earnings are still scheduled for Nov. 17 . Second, who will fund AI now. Newcomer reports that Huang personally led Nvidia's strategy of investing in its own customers, and that interim CEO Colette Kress is likely to rein it in . One podcast panelist estimated Nvidia often took 10–20% of the rounds it joined, and said "that money is going to dry up" . Databricks' Ali Ghodsi called the crisis "bad for the ecosystem, bad for neoclouds" . General Catalyst's Hemant Taneja suggested a weaker Nvidia could mean more competition in AI chips . Garry Tan signed the "StandWithJensen" letter calling for due process .
The capital Nvidia may stop providing is about to come from Anthropic instead. Its prospectus sets a $70–78 range, with pricing Nov. 18 and trading Nov. 19. Seven compute suppliers, including Nvidia, Google, AMD, Microsoft and TSMC, will buy $26B of non-voting stock at the IPO price. Bloomberg reports orders at about 6x the shares available . One trillion-dollar allocator told Harry Stebbings it is worried less about this $80B raise than about whether anyone can fund the next $100B, because that layer of capital is "very thin" . Separately, Greg Brockman said OpenAI's annualized revenue grew 70% in Q3 and that enterprise now accounts for most of it .
The mood at Newcomer's Cerebral Valley summit:
- Enterprise buyers are now focused on cutting AI costs, using purpose-built chips, open-source models and optimization .
- Startups worry that the frontier labs and Big Tech will control who gets access to the best models .
- Speakers said coding is the one clear killer app and that applications beyond it are "fuzzy" .
- 80% of attendees said AI is in a bubble, though most thought it was a problem for next year or later .
- The median company on the new AI 100 list is valued at $9.3B, almost double the year-ago figure .
Frontier prices are falling
Anthropic priced Fable 5.2 and Mythos 5.2 at $8/$40 per million input/output tokens, a 20% cut from the $10/$50 frontier level. The models are also about 30% faster, which lowers cost per token by roughly 23%. Jamin Ball reads the cut as passing efficiency gains through to customers during a land grab, and expects more of the same .
Garry Tan's open-source harness evals show that the agent wrapper around a model now drives cost more than it drives success rates:
- With the model and tasks held fixed, seven model–harness pairs all solved 71–79% of 20 tasks, and their confidence intervals overlapped.
- Cost per solved task was $0.17 for Codex, $0.22 for Claude Code and $0.44 for OpenClaw .
- When a knowledge base was connected with a company-wide token, OpenClaw and Hermes returned 121–123 records the requester was not authorized to see .
- Tan discloses that YC incubated QM, YC invested in Hermes, and gstack and gbrain are his own projects .
In a separate run of 52 tasks, Fable 5.2 matched Opus 5.5 (82.7% vs 84.6%) but cost 2.8x as much per solved task .
Aravind Srinivas says most of Perplexity's revenue growth this year has come from usage-based workflow automations, and calls net dollar retention "very high." He adds that routing tasks to cheaper models cuts usage revenue in the short term, but usage then grows enough to make up for it . He also says Perplexity's coding agents built a database that replaced DynamoDB for its trillion-page index, saving "several tens of millions" a year .
Deals
- LangChain: $300M Series C at a $3B valuation. It says more than 7,000 companies use LangSmith , including over 35% of the Fortune 350, and that its team has grown more than 4x this year to over 450 .
- Zipline: $1.5B at $21.5B post-money, 2.8x its January valuation, after Walmart signed on for 300 more sites . Rory O'Driscoll says the price is a heavy bet on the Walmart contract .
- fal: $1.3B at $16B, about 20x its reported $800M annualized revenue .
- Path Robotics: $300M Series E led by Georgian at $2.45B. Revenue is up 17x in 18 months, customers include HII (a $600M deal) and Lockheed , and its welding robot dog has 50 preorders .
- Intelligence (YC S25): reached a $60M annualized run rate in about a year. Its Design Arena product has 7M+ users and turns their real-world use into evaluation data for model labs .
- argenx–Unnatural Products: $550M upfront plus up to $595M in milestones for the macrocycle company, which is working on an oral drug against FcRn .
- Dialpad–Ada: an all-share deal valuing Ada at about $430M, against a reported $1.2B in 2021 . Jason Lemkin argues it offers no real liquidity .
Palantir grew Q3 revenue 96% to $2.313B , with net dollar retention of 165% . Bookings tell a different story: total contract value rose only 6%, and U.S. commercial contract value fell from $2.13B to $1.46B in a quarter. Management attributes this to shorter contracts .
Security and fragility
Wiz CTO Ami Luttwak says AI can now carry out in 20 minutes attacks that used to take skilled attackers weeks. He tells startups to build automated testing and patching into development from day one . a16z adds that developing a working exploit used to take a median of 22 days, and recent AI-assisted examples took hours .
Two large outages were not caused by AI or attacks, as far as anyone has said. Microsoft attributed its 365 outage to an earlier network-capacity upgrade, "not related to cyber or AI / agents" . The FAA grounded flights nationwide days after rolling out its SMART AI air-traffic tool across the country. The Transportation Secretary blamed a communications issue, DHS says it is "looking at" SMART, and the tool's maker denies any link .
Open models and frontier tech
- llama.cpp reached v1, its first fully stable major release .
- Thinking Machines released Inkling 2 Small's weights under Apache 2.0, about a week after launch. It is a 594B-parameter MoE with 17B active parameters .
- Fortune reports that OpenAI disbanded its robotics team, betting that its general models will run robots. This is from the headline only .
- Google DeepMind's AlphaGenome 2 identified 30% of variants believed to be causal across 28 immune cell types, up from 16% for the previous version .
- a16z's AI-pharma thesis says AI could raise drug-approval odds and shorten timelines. It currently takes about $2B and 13 years to develop a drug , and the firm expects wet-lab demand in the $90B CRO market to "explode" . It warns that biology is short on data and that how much feedback loops can actually be shortened is still unknown .
- The episode reports that Nvidia CEO Jensen resigned after 33 years and CFO Colette Crest became interim CEO; panelists said allegations of smuggling were unproven and the reasons for the departure remained uncertain. One panelist estimated Nvidia had supplied 10–20% of AI funding rounds it joined and predicted its investments could contract under CFO leadership; the discussion framed reduced circular financing as a possible de-risking, but warned that less Nvidia capital could also weigh on AI startups and infrastructure.
- Demis Hassabis described current coding tools as making human engineers roughly 3–5x more productive while people still review, architect, and write code; he identified closed-loop recursive self-improvement without human review as a riskier next stage, citing difficulty maintaining control and potentially alien outcomes.
- Anthropic put Claude Whiteboard and Sheets into beta, made Claude Data generally available, and launched Claude Meetings inside Google Meet on paid plans. The episode also reports Claude connectors for apps including Notion, Asana, Canva, and Dropbox, supporting a strategy of doing work through an agent interface; panelists noted that incumbents retain advantages in distribution, enterprise permissions, compliance, and installed base.
- Planet Labs launched Planet AI, a natural-language search app for a 10-year archive of more than 3,000 layers of daily satellite imagery; it was free for eligible users with usage limits. Separately, a researcher said 48 agents searched 1,200 km² of public NASA lidar data and flagged a possible Mayan site; Mexico’s National Institute of Anthropology reportedly said it appeared to be an original finding.
- The episode presented Jensen Huang’s reported departure from Nvidia as a breaking story based on partial information: it said Nvidia’s CFO was serving as interim CEO while the board searched for a successor, and the stock had fallen 15%; the speakers cautioned that the story was incomplete.
- Panelists said Huang had been central to Nvidia’s capital backing of startups, data centers, and infrastructure, so his departure could slow AI investment. They cautioned that rivals could not immediately replace Nvidia’s supply: scaling chips and securing foundry and HBM capacity remain constraints, though Huawei could benefit if Nvidia’s pace faltered for years.
- The discussion said Anthropic’s IPO target was 46% above its last private-round valuation after its run rate doubled; it cited an analyst bull case of a $4.2T valuation on $281B in projected 2028 revenue and said demand was six times oversubscribed. Speakers also warned that Nvidia-related and broader AI-market risks could affect IPO pricing.
- Anthropic was described as expanding Claude into a broad software bundle—including Meetings, Whiteboard, Sheets, Personal Finance, and Legal—with speakers arguing that bundling could challenge SaaS incumbents and reduce interoperability friction. The discussion also characterized Anthropic as marketing recursive self-improvement and winner-take-all prospects, while raising safety concerns.
- A panelist working in biology said AI was already accelerating molecular discovery, in-silico testing, and product development, citing weekly breakthroughs and use of Anthropic for substantial biology workloads; this was presented as personal experience, not a quantified industry-wide result.
- The guest says AI models can now find and exploit complex vulnerabilities, open-source models are catching up, and attacks that took top attackers weeks or months can be carried out in about 20 minutes. The tracked list of attacked AI-development platforms grew from 9 to 15 in October; the guest identifies the platforms’ AI keys as a reason they are targeted.
- The PHP incident illustrates the patching gap: about half of customers patched within the first 2–3 days, but the guest says resolving the widespread vulnerability could take years and some older PHP versions receive no patch; vulnerability information can leak before a patch is available, and Linux fixes may take weeks or months to reach distributions.
- For startups, the guest recommends designing from the outset for automated patching across development, testing, CI/CD, and DevOps. For startups holding AI keys, the advice is to limit key usage to cap charges if keys are stolen and to prioritize secure design, including sandboxing and isolation.
- The guest argues that defenders should continuously test unauthenticated, internet-exposed attack surfaces from the outside, prioritizing this over broad code scanning. The guest says red-agent use is nearing full coverage among its customers, while adoption across the industry remains insufficient.
- For AI products at scale, the guest describes cost-aware model routing as a core engineering challenge: combine models with different capabilities, speed, and cost, using deterministic and cheaper steps before escalating to more expensive models rather than running the most advanced model on every event.
-
Garry Tan shared the open-source
g-harness-evalsrepository, which compares agent harnesses while holding models and tasks fixed. In 20 development tasks, seven model–harness configurations scored 71–79%, with overlapping 95% confidence intervals; reported cost per successful task was $0.17 for Codex, $0.22 for Claude Code, and $0.44 for OpenClaw. In the same evaluation, initial context sizes ranged from about 12,900 tokens for Codex to 20,613 for Hermes; in one Sonnet test, prompt-cache reads and writes accounted for 87% of OpenClaw’s bill. - The tests also surfaced agent execution and access-control risks: gstack’s instructions loaded into Opus 5.5 but its steps were never executed across 46 tests, while a hook was bypassed through Bash 40 times. With gbrain using a company-wide token, OpenClaw and Hermes returned 123 and 121 records, respectively, that requesters were not authorized to see; scoping retrieval to the requester’s permissions reduced unauthorized results to zero.
- The repository reportedly includes raw records that can be checked locally without an API key. Tan disclosed that QM is YC-incubated, YC invested in Hermes, and gstack and gbrain are his own projects—relevant context for weighing the comparisons.
- Perplexity is shifting focus from mass-market consumers toward high-value business users, entrepreneurs and enterprises. Srinivas said usage- or token-based revenue is growing through repeat workflow automations such as research, monitoring, marketing and corporate development; customers may use up included credits and pay for more. He described revenue as sticky with high net dollar retention, while noting that lowering task costs can temporarily reduce usage-based annualized revenue even as usage expansion lifts total revenue.
- Perplexity’s product strategy extends from accurate answers into deep research, browsing agents, cloud-based agents and persistent work teammates. Srinivas argued that a model-agnostic harness—backed by its own sandboxes, routing, connectors, search and browsing—is a key source of value as models improve, with safety and enterprise access controls also important.
- Srinivas said Perplexity used coding agents to build a database from scratch and replace its use of AWS DynamoDB for its web-page index, saving the company several tens of millions of dollars annually.
- Srinivas said NVIDIA is one of Perplexity’s largest investors and described multi-year collaboration on inference libraries, open-source work and Neotron training data, with further projects planned. He also said Perplexity had been post-training its own models and lowering serving costs, and put a possible IPO window at anytime from then through 2028, while declining to share numbers.
- Market backdrop: a16z puts the top 30 pharmaceutical companies at roughly $5T in market capitalization and Eli Lilly above $1T; analysts cited in the article expect Lilly’s GLP-1 portfolio to exceed $100B in annual sales by 2030.
- a16z’s AI thesis is that improving drug-candidate success rates and shortening development timelines could lower the risk-adjusted cost of medicines; it cites an average 13-year development process, nearly $2B present-value cost, and fewer than 5% of candidates reaching FDA approval. It expects faster candidate generation to increase demand for experimental data, pointing to data providers and lab automation in a $90B CRO market ($30B discovery/preclinical and $60B clinical trials).
- The startup opportunity spans selling data and technology—including lab automation, predictive biology, scientific-reasoning agents, molecular design, and model-deployment tools—or building higher-risk, more capital-intensive full-stack drug developers with greater potential upside. Examples of full-stack companies named include Recursion, Isomorphic, insitro, Xaira, Relay Tx, and Octant Bio.
- Pharma partnerships offer an early commercial signal: a16z cites Isomorphic Labs agreements with Novartis and Eli Lilly worth up to $1.2B and $1.7B, respectively, in potential milestone payments, but says the key test is whether model gains produce better drugs entering clinical trials. The thesis remains uncertain: biology is data-poor and complex, drug designs still require wet-lab and human validation over long timelines, and how much startups can shorten feedback loops is unknown.
- Drug development averages 13 years and nearly $2B in present-value cost, with fewer than 5% of drug candidates reaching FDA approval; AI could increase success odds and shorten timelines, potentially making otherwise uneconomic targets viable. Biology remains data-poor, and drug designs still require wet-lab and human validation over long feedback loops.
- Startup opportunities span biopharma tools and infrastructure—data and lab automation, predictive biology, scientific reasoning, molecular design, and enterprise deployment—and full-stack companies developing their own medicines; the latter require more capital and risk but offer greater upside. The article puts the CRO market at $90B and expects demand for experimental data and wet-lab services to grow as candidate generation speeds up.
- Pharma partnerships provide early commercial signals: Isomorphic Labs has agreements with potential milestone payments of $1.2B with Novartis and $1.7B with Eli Lilly, while Chai, Boltz, BigHat Bio, Nabla Bio, Genesis Molecular AI, and Profluent also have pharma partnerships. The article says the key test is whether model progress produces better drugs entering clinical trials; Anthropic has opened a wet lab and announced drug candidates, while OpenAI acquired Orchestra Bio to build biotech execution capabilities.
- a16z frames pharma as a hits-driven market: the top quarter of drugs generate about 85% of revenue, while successful drugs can deliver years of patent-protected cash flow. It argues AI could raise drug-development success rates and reduce time and cost; the article puts current development at nearly $2B in present-value cost and 13 years on average, with fewer than 5% of candidates reaching FDA approval.
- Startups can sell data and technology—such as lab automation, predictive biology models, scientific reasoning, molecular design, and enterprise deployment—or build vertically integrated AI therapeutics companies. The latter approach requires more capital and carries more risk but offers greater upside through ownership of drug assets.
- Pharma partnerships offer an early commercial signal: Isomorphic Labs has agreements with Novartis and Eli Lilly involving $1.2B and $1.7B in potential milestone payments, respectively; a16z says the key test is whether model advances produce better drugs entering clinical development. Translation remains uncertain because biology is data-poor and drug designs ultimately require wet-lab and human validation on long timelines.
- Google DeepMind’s AlphaGenome 2 predicts DNA effects for a specified tissue, cell type, cell state, or data from previously unseen cells; trained on more than 107 million cell profiles across 68 human and mouse tissues, it identified 30% of variants considered causal across 28 immune cell types, versus 16% for AlphaGenome 1. The source says it still misses most variants, but could help researchers computationally prioritize disease-linked variants that often require real-world experiments to interpret.
- Argenx announced it would acquire Unnatural Products for $550 million upfront plus up to $595 million in development and regulatory milestones. The companies had partnered since the prior year; their work includes an oral macrocycle targeting FcRn, and the Unnatural Products team is to become argenx’s peptide-discovery hub.
- Path Robotics raised a $300 million Series E led by Georgian at a $2.45 billion valuation; the article reports revenue grew 17x in 18 months. Its Obsidian system plans and adjusts welds for variable joints rather than repeating a fixed path; named customers include Lockheed Martin, Saronic, and HII, with the article also reporting a $600 million HII deal. Its welding robot dog had 50 preorders for shipyards and construction sites.
- SpaceX ordered a turnkey heterojunction solar-cell production line from SINGULUS for delivery to its Bastrop satellite factory in the first half of 2027; the first line is worth a little over €60 million, with further orders and more than 100 GW of production equipment described as the plan. The article cautions that the current commitment is €60 million and treats the much larger scale as an ambitious promise, not established deployment.
YC CEO Garry Tan publicly backed Jensen, saying he deserves due process. The linked open letter calls for a fair process and the truth, citing Jensen’s 33 years building NVIDIA.
In Garry Tan’s 52-task coding evaluation on Claude Code 2.1.322, Fable 5.2 solved nearly as many tasks as Opus 5.5 (82.7% vs. 84.6%) but cost 2.80× more per solved task; Tan recommends Opus 5.5 as the coding default. He cautions that Opus already solves most of these tasks, so harder tasks are needed to distinguish the models.
Arav Srinivas highlighted a Perplexity demo in which rendering was orchestrated across 48 sandboxes in parallel, completing the process in three hours . The linked report describes a “Video Production teammate” used to recreate the Pantheon, gather survey dimensions and recent photos, build a three.js renderer with procedural shaders, and produce 60-fps video with motion blur; each frame took 80 seconds to render .
Garry Tan says he made an “idea-minder” skill intended to let a personal agent recursively self-improve as it is used, and links a page titled “idea-miner-what-to-build.”
Intelligence (S25) is building benchmarks for hard-to-measure AI capabilities; its first product, Design Arena, lets people use frontier models to create websites, images, videos, and other creative work, turning those interactions into data that helps model labs assess where models succeed or fail. Design Arena has more than 7 million users across 192 countries, and @Intelligence_ai reached a $60 million annualized run rate in about a year.
- a16z says a working exploit that once took a professional a median of 22 days to develop has taken hours in recent AI-assisted examples.
- Wiz co-founder and CTO Ami Luttwak warns that after attackers gain access, an attack can take 20 minutes to steal secrets and customers’ AI keys; startups can be targets even if they are not large. He advises limiting AI-key usage to curb charges if keys are stolen and prioritizing security when targeted.
Jason says the leak of Rubio’s memo prompted internal finger-pointing in the administration and estimates a greater-than-50% chance that the New York Times’ source was China hawks inside the administration; this is his prediction, not a confirmed attribution. In the linked post, he says those hawks may favor a total ban on chips to China for national-security reasons, and separately speculates that the CCP could seek to weaken the U.S. AI lead; neither is evidence of an announced policy change or a confirmed leak motive.
Srinivas called a VC-diligence vignette “Interesting”: a Series B SaaS company claims an organization as a customer, but a colleague says it still has a two-year contract while having stopped using the tool months earlier because “Computer” did the job 3× better. For investors, the scenario cautions that contracted customer status may not reflect active use or retention; it is presented as a vignette, not a verified churn event.
- Wiz co-founder and CTO Ami Luttwak says AI can compress cyberattacks that once took skilled attackers weeks or months into 20 minutes; he describes attackers stealing startup secrets and customer AI keys within that window, and warns that any startup holding something valuable can be targeted, not just large companies.
- For startups, Luttwak recommends limiting AI-key usage to curb charges if keys are stolen, while a16z’s discussion emphasizes building automated security testing and patching into development from the outset.
Jason says many people were tuning in live on X and that he is focusing more on X Live now that it has a new Clipping feature; this is an anecdotal creator-engagement signal, not evidence of broader adoption.
Wiz co-founder and CTO Ami Luttwak says AI can carry out cyberattacks in 20 minutes that previously took skilled attackers weeks or months. He argues companies need to continuously test their own systems with the latest AI models, and startups should build automated testing and patching into development from the outset; the discussion also emphasizes security architecture over simply buying more tools.
Weekly Dose of Optimism #219

Cover Image by Runway (opens in new tab)
Hi friends 👋,
Happy Friday and welcome back to our 219th Weekly Dose of Optimism!
What a week. After two affairs emerged - one with an alleged Chinese spy and one with a direct report - Nvidia founder and CEO Jensen Huang resigned (opens in new tab). Sources say the affairs are the tip of the iceberg and that heavier shoes will drop.
But progress marches on, as evidenced by everything in this week’s Dose. It’s going to take more than a wandering Huang to keep us down.
By the way, inspired by Readwise launching Readwise Books (opens in new tab), I had Codex turn all of my essays into epubs that you can download and read on your book reader of choice, because while they’re long essays, they’re actually pretty short books! You can find and download all of them, including Of Miracles and Moats (opens in new tab), at not boring press (opens in new tab).
Let’s get to it.
This Week’s Weekly Dose is brought to you by… Runway (opens in new tab)
I have been having so much fun with Runway (opens in new tab) as this quarter’s presenting sponsor. The product keeps getting better, and expanding, every week. Personally, I’m hooked to making videos - whether explainers for the Dose or attempts to make short films - and I think you’ll really enjoy it, too. Try it for work, or try to become the next Scorsese (opens in new tab).
*Runway (opens in new tab) is building foundational AI for how the world creates. 65M+ people use Runway to generate, edit and produce video, images and audio with 80+ top media models. You can read my essay (opens in new tab) with co-founder Anastasis Germanidis to learn more on where Runway is headed beyond video.
Nvidia, Amazon, Lionsgate, Chime, and 95%+ of the Fortune 100 are part of a growing community of teams, founders, and independent creators using Runway to make national TV spots, social ads at scale, launch videos and more.
You can also use Runway in ChatGPT, Claude, Grok, Cursor, Replit and more via the Runway MCP (opens in new tab).*

So, uhhh, pretty good time to be Google, huh?
On Wednesday, as Nvidia was in turmoil, the maker of GPU competitor TPUs, and our favorite chef of models outside of your plain vanilla LLM, released AlphaGenome 2.
Last year’s AlphaGenome 1 took a million letters of DNA and predicted what they do, but averaged across whole tissues. It was very cool! But averages can hide things, like variants that might cause disease in only one rare cell type or only after a cell gets activated.
AG2 takes the same million letters plus a condition, which can be a tissue, a cell type, a cell state, or data from a few dozen of your own cells that it has never seen before, and it predicts what the DNA does there specifically. It trained on more than 107 million individual cell profiles from 68 human and mouse tissues. On a benchmark of 28 immune cell types, it found 30% of the variants scientists believe are causal, versus 16% for the old model.
As longtime readers know, my process for figuring out whether something in bio is legit is to text Elliot, but this time, he tweeted before I had to:
Genome-wide association studies have handed us an enormous pile of DNA variants linked to diseases, and for most of them, scientists are still trying to figure out which gene they touch or which cell they act in, which often takes a lot of real world experimentation. That’s a big part of why genetics - we mapped the whole human genome! you can now get yours done for like \$100! - hasn’t turned into drugs as fast as everyone hoped. But AG2 can pick up signals from all of that data computationally, which means we’ll be able to rev through them to (hopefully) find cures much more quickly.
AG2 still misses most of them (30% is 30%), but going from 16% to 30% in one generation is great progress, and there’s a lot scientists can do with that 30%.
Bad time to be a disease.

Real bad time to be a disease, because even if you can use things like AG2 to find targets, you still have to drug them. Which is what macrocycles do.
Macrocycles are ring-shaped peptides that sit somewhere between the small molecules that come in pills and antibodies that need to be injected. The promise is the precision of a biologic in a pill that can slip inside cells to hit targets antibodies can’t reach. Think something like an oral GLP-1 or cancer therapeutic.
Macrocycles are what not boring capital portfolio company Unnatural Products does, and now, it will be doing them inside of argenx. On Monday, argenx announced that it’s acquiring UNP for \$550 million in cash upfront and up to \$595 million more if it hits development and regulatory milestones. Big win for Cam, Josh, and the UNP team!
argenx and UNP have been partners since last year, and argenx was already an investor, so it knows what it’s buying. They’ve been working on a pill that goes after FcRn, the same target as Vyvgart, the argenx drug that did \$1.72 billion in sales last quarter. The team will keep working out of Santa Cruz, where they have huge lush trees right outside the window, and will become argenx’s home for peptide discovery.
Naturally, I’m very excited about the win, and we should all be excited to get more of the potential miracle cures we talk about here delivered in effective pill form in the years ahead.
Good welders are insanely valuable. I remember touring SpaceX a few years back and hearing them talk about the one guy who could weld everything in hushed tones. Just this week, I was talking to someone about a golden gloves welder somewhere else who pulls \$1 million a year. Welding is the same story we often hear: not enough welders, let alone great welders, to make all of the things we need to make.
Back in Dose #214 (opens in new tab), we covered Anduril’s \$3.7 billion Arsenal-2 shipyard, its answer to the US’ shipbuilding problem. But even with big shipyards, we’re going to need a lot of welders. They just might not all be human welders.
Path Robotics (opens in new tab), which brothers Andy and Alex Lonsberry started in Columbus, Ohio in 2018, makes robots that weld, which is harder than it sounds! Normal welding robots just repeat a programmed path, but that doesn’t work when the parts in front of them are a little different every time, which they always are, which is why humans still do most of the welding, and why even among humans, the ones who can weld anything are so valuable. Path’s model, Obsidian, tries to make robot welders as effective as golden gloves welders by looking at the actual joint each time, planning the custom weld, and adjusting as it goes.
On Tuesday, Path announced a \$300 million Series E led by Georgian at a \$2.45 billion valuation. Its revenue is up 17x in 18 months, and customers include Lockheed Martin, Saronic, and HII, the Navy shipbuilder, with which Path signed a \$600 million deal earlier this year.
They also make a robot dog that welds (Rove, a Boston Dynamics quadruped with Path’s tech on it) with 50 preorders, headed to shipyards and construction sites next year.
If we want to build big things, we’re going to need a lot of welders, whether of the human, robot, or robot dog variety. Learn to weld.

Good week to be Elon Musk. He has people thinking he’s going to hire Jensen to run Terafab, but while they’re thinking about, they’re also thinking about how useful it is to be basically fully vertically integrated and control your own destiny, even if it means sending your data centers (Starmind) up to space on your rocket (Starship), maybe one day filled with your own chips (Terafab), but for now in partnership with Nvidia (???), to run on the unlimited power of the sun (???).
Looks like SpaceXAI will be making solar panels, too. On Tuesday, SINGULUS, a small German company that makes the machines that make solar cells, announced that SpaceX signed a contract for a turnkey heterojunction (HJT) cell production line, to be delivered in the first half of 2027 to SpaceX’s satellite factory in Bastrop, Texas.
That first line is worth a little over €60 million, but SINGULUS says that more are coming, and that the plan is to scale to “more than 100 GW of production equipment.”
That, to be clear, is a preposterous number. Each Starmind is designed to have a 75-meter wingspan and a 210 kW solar array, so if my (machines’) math is right, 100GW per year is enough for something like 475,000 satellites. Every year. There are about 15,000 active satellites in orbit right now.
On the other hand, as it stands, this is a €60 million commitment whose announcement was probably worth much more than €60 million to SPCX’s market cap in terms of making Starmind look more serious. A promise to build 475,000 space data centers a year is also exactly the kind of thing you’d expect to hear - and for people to take at least somewhat seriously - if we were in a bubble (opens in new tab).
But A+ for ambition, and if SpaceX ends up building a ton of solar panels and doesn’t end up sending them all up to space to create a sentient sun, then consumers will win again in the form of more cheap, clean energy. Never bet against the American consumer.
via @nasasolarsystem
Speaking of putting ambitious things in space… In 1977, NASA launched two twin probes, Voyager I and Voyager II, each carrying Carl Sagan’s Golden Record. To exploit a rare alignment of the outer planets that let one spacecraft slingshot from one to the next, Voyager 2 launched first, on August 20th, and Voyager 1 followed on September 5 on a faster path.
Between 1979 and 1981, both flew past Jupiter and Saturn, discovering active volcanoes on Io and detail in Saturn’s rings. Then Voyager 1’s passed close enough by one of Saturn’s moons, Titan, to fling itself up and out of the plane of the planets, while Voyager 2 continued in our own solar system. In 1986, it passed Uranus, and in 1989, it reached Neptune.
The next year, on Valentine’s Day 1990, Voyager 1 took the famous Pale Blue Dot picture that I used to frame Us Against Spacetime (opens in new tab).

In 1986, Voyager 2 passed Uranus (insert butt joke here) and in 1989, Neptune. It’s the only human-made craft to make it to either one.
Our solar system is so big. But it is tiny tiny tiny compared to the universe.
Voyager 1 crossed the heliopause into interstellar space in 2012, 35 years after it left Earth.
And next Wednesday, 14 years after that, 49 years after the journey began, Voyager one will pass one light-day away from home.
That is a long ways away, the furthest anything we’ve ever made has voyaged by far, and STILL it’s nothing. The Milky Way is something like 100,000 light years across, and the Observable Universe (not the whole thing, just what we can see) is 93 billion light years across. So after this entire 49 year trip, Voyager 1 has traveled just one 34-trillionth of the way across the Observable Universe. At this pace, it would take 1.67 quadrillion years to do the whole thing, or 120,000x longer than the universe has been around.
So this one is both a celebration of our ability to engineer a thing that can travel a whole light-day away, and a reminder that we are just a minuscule part of this big, beautiful universe. There is much left to explore.
Video by Runway (opens in new tab)
From outer space to inner space we journey.
I can’t really think of anything that would be better for humanity than discovering that psychedelics reverse brain aging and fight neurodegenerative diseases.
Back in Dose #196 (opens in new tab), we covered the case of an octogenarian Japanese-American woman with a decade-long history of Alzheimer’s who’d been given a 5mg dose of psilocybin and regained a number of functions, including holding an autobiographical conversation, dressing herself, retrieving contextual memory, and walking independently. The improvements weren’t permanent, but they showed that the person was still in there, and that psilocybin might hold the key to getting them back out.
Now, in a new study in Aging Cell, Aurora Savino, Francesco Iorio, and colleagues found that LSD might reverse brain aging, at least in rats.
As the brain ages, its gene expression drifts in a predictable direction. The genes that maintain synapses and dendrites quiet down, and the ones that build glia and blood vessels get louder. A team in Milan and Turin mapped that drift across 3,086 human prefrontal cortex samples, from donors aged two days to 106 years, then went searching for an intervention that could push back on the drift.
They, like so many seekers before them, found LSD. In chronically dosed rats, and with a single dose in mice, it opposed the aging signature more strongly than exercise or an enriched environment, the two interventions scientifically proven to be good for old brains. In terms of switching on the right genes, it outranked all 193 drugs in a reference database.
MDMA and alcohol had the opposite effect: they made brains look older, which makes sense if you’ve ever woken up after a night of drinking too much.
But LSD… it gets better! In a dish, LSD repaired mouse neurons that had been damaged by amyloid-β, the protein that builds up in Alzheimer’s, restoring both their branches and their synaptic proteins.
I’ve long told you I’m terrified of getting Alzheimer’s, and that I get easily excited when there’s promising news, even if it’s early. LSD’s success in rat and mouse brains doesn’t guarantee success in human brains. But I guess there’s only one way to find out.
EXTRA DOSES: Science Breakthroughs, Aquaterra, The Method, BAAJA, Lilly in PA
- Google DeepMind’s AlphaGenome 2 predicts DNA effects for a specified tissue, cell type, cell state, or data from previously unseen cells; trained on more than 107 million cell profiles across 68 human and mouse tissues, it identified 30% of variants considered causal across 28 immune cell types, versus 16% for AlphaGenome 1. The source says it still misses most variants, but could help researchers computationally prioritize disease-linked variants that often require real-world experiments to interpret.
- Argenx announced it would acquire Unnatural Products for $550 million upfront plus up to $595 million in development and regulatory milestones. The companies had partnered since the prior year; their work includes an oral macrocycle targeting FcRn, and the Unnatural Products team is to become argenx’s peptide-discovery hub.
- Path Robotics raised a $300 million Series E led by Georgian at a $2.45 billion valuation; the article reports revenue grew 17x in 18 months. Its Obsidian system plans and adjusts welds for variable joints rather than repeating a fixed path; named customers include Lockheed Martin, Saronic, and HII, with the article also reporting a $600 million HII deal. Its welding robot dog had 50 preorders for shipyards and construction sites.
- SpaceX ordered a turnkey heterojunction solar-cell production line from SINGULUS for delivery to its Bastrop satellite factory in the first half of 2027; the first line is worth a little over €60 million, with further orders and more than 100 GW of production equipment described as the plan. The article cautions that the current commitment is €60 million and treats the much larger scale as an ambitious promise, not established deployment.